Built on research: our path to success started before our involvement, with the concept and technology already demonstrated in an EU FP7 project, and the first prototype developed in 2014.
In 2018 we established the optimal project team for ensuring a successful innovation, and our research project, HyperSension, received funding from the Norwegian Research Council.
Accelerating towards a market launch in 2022.
This is the essence of the product. The goal is to reduce the mortality rate of undiagnosed and untreated high blood pressure.
The company has a stated policy that half of all employees in the company must be women. The company has both a female general manager and a female research manager.
Ambitions of global presence and to become a great workplace with employees in several countries.
The company is based on research and innovation, and has a policy that products and services will be created through research.
The plan is for production to be carried out in Europe as much as possible, and we have great focus on the external environment and rationalization of production and transport
The company is already ISO-14001 certified (External Environmental Management System) and has processes and procedures for climate-friendly solutions, requirements for suppliers related to climate, etc.
Our product is the result of a unique collaboration between research institutions (Sintef and Ullevål), the primary health service (Ullevål and GPs at Sandefjord Helsepark) and the business community. This is a stated goal going forward, to further develop the products through collaboration and effective research